Launching a cosmetic product in the European Union requires several connected workstreams:
- product development
- supplier documentation
- stability and microbiology
- safety assessment
- packaging
- claim substantiation
- PIF preparation
- CPNP notification
- production and distribution
The individual activities are manageable. The difficulty is completing them in the correct order.
A product launch can be delayed even when every supplier completes its own task on time. One outdated formula, missing allergen declaration or late packaging change can invalidate work completed elsewhere.
How long does an EU cosmetic launch take?
There is no universal timeline.
The duration depends on:
- formula complexity
- product type
- document completeness
- testing requirements
- packaging
- supplier response times
- claims
- target population
- product variants
- Responsible Person readiness
A simple, well-documented product may move quickly. A complex product with incomplete raw-material data, an untested preservation system or ambitious claims can require significantly more work.
The better planning question is not:
How quickly can we get a CPSR?
It is:
When will the complete final product, its evidence and its documentation be ready for market placement?
Phase 1: Product concept and regulatory screening
Before finalising the formula, define:
- intended product function
- target users
- application area
- frequency of use
- rinse-off or leave-on status
- target EU countries
- planned claims
- packaging format
- likely product classification
This early review can identify whether a product risks falling into another regulatory category because of its composition, presentation or claims.
Common delay
The marketing team develops medicinal, biocidal or therapeutic-style claims after the product has already been designed as a cosmetic.
Better approach
Review the intended claims and product presentation before the development brief is approved.
Phase 2: Formula development and ingredient screening
During formulation, review:
- prohibited ingredients
- restricted ingredients
- permitted preservatives
- permitted colourants
- permitted UV filters
- allergen implications
- nanomaterials
- impurity concerns
- vulnerable-user considerations
The safety assessment is easier when regulatory constraints are addressed during development instead of after formula freeze.
Common delay
A restricted ingredient or concentration issue is identified only when the safety assessor receives the final formula.
Better approach
Complete a preliminary regulatory and toxicological formula review before ordering pilot production.
Phase 3: Supplier-document collection
Collect documents for every raw material.
The required package may include:
- INCI and composition
- specification
- certificate of analysis
- safety data
- impurity profile
- allergen declaration
- fragrance documentation
- microbiological specification
- natural-origin information
- nanomaterial information
- toxicological information
Common delay
The formula is frozen, but suppliers take weeks to answer composition or impurity questions.
Better approach
Start document collection as soon as raw materials enter the development shortlist.
Phase 4: Formula freeze and version control
Testing and assessment should refer to a controlled formula version.
Record:
- formula number
- version
- date
- supplier
- raw-material grade
- concentration
- manufacturing process
- batch identification
Common delay
A fragrance, preservative or viscosity modifier is changed after testing, but the previous reports continue to be used.
Better approach
Create a formal change assessment for every post-freeze modification.
Phase 5: Testing strategy
Depending on the product, evidence may include:
- stability testing
- microbiological-quality testing
- preservation-challenge testing
- compatibility testing
- chemical analysis
- packaging assessment
- claim-substantiation studies
The test plan should be based on the product’s risk and intended use.
Common delay
Every available test is ordered without determining which regulatory question it should answer.
Better approach
Classify tests as:
- required for the planned assessment
- recommended to reduce uncertainty
- optional for commercial or claim purposes
Phase 6: Stability and packaging evaluation
Stability work should consider the actual packaging intended for market.
Relevant observations may include:
- appearance
- odour
- colour
- pH
- viscosity
- separation
- leakage
- container deformation
- product loss
- compatibility
- shelf-life indicators
Common delay
The product is tested in laboratory packaging while the final commercial container is still being selected.
Better approach
Confirm the packaging system early enough for representative stability and compatibility work.
Phase 7: Microbiological assessment
Water-containing cosmetics and products exposed to repeated consumer contact may require specific microbiological evidence.
Common delay
The challenge test is planned only after the safety assessor requests it.
Better approach
Assess the preservation strategy during development and reserve sufficient time for testing and any necessary reformulation.
Phase 8: Claim-evidence planning
Claims should be connected to appropriate evidence.
Possible evidence sources include:
- scientific literature
- ingredient data
- instrumental tests
- in-vitro studies
- consumer studies
- clinical studies
- expert assessment
EU claims must comply with common criteria and be consistent with evidence in the PIF.
Common delay
Packaging and campaign copy are approved before anyone confirms that the final product evidence supports the wording.
Better approach
Create a claim-evidence matrix before artwork approval.
Phase 9: Cosmetic Product Safety Report
The qualified safety assessor evaluates the complete product information and prepares Part B of the CPSR.
The EU requires the safety assessment and CPSR before the cosmetic product is placed on the market.
Common delay
The assessor receives incomplete or inconsistent documents and must begin several rounds of questions.
Better approach
Perform a pre-assessment completeness check.
Phase 10: PIF compilation
The Product Information File connects the safety report to the wider product documentation.
It includes:
- product description
- CPSR
- manufacturing method and GMP statement
- claim evidence where relevant
- animal-testing information required by the Regulation
The PIF must be kept current and retained for ten years after the final batch is placed on the market.
Common delay
Files exist across multiple suppliers, inboxes and folders but have never been compiled into a controlled PIF.
Better approach
Use one document index, clear ownership and controlled versioning.
Phase 11: Label and artwork approval
Review the final artwork against:
- the approved formula
- CPSR warnings
- INCI information
- Responsible Person details
- product function
- nominal content
- durability information
- batch identification
- country of origin
- claim evidence
- market-language requirements
Common delay
The packaging order is placed before the CPSR and final ingredient review are complete.
Better approach
Create a formal “regulatory approved for print” gate.
Phase 12: CPNP notification
The Responsible Person submits the required product information through CPNP.
The CPNP is a free EU notification system. A correctly notified product does not generally require additional national cosmetic notification, but notification itself is not a safety approval.
Common delay
The team assumes that a manufacturer or consultant has already completed notification, but responsibility and access were never documented.
Better approach
Assign one named owner and retain confirmation within the product file.
Phase 13: Final market-readiness review
Before release, confirm that:
- the marketed formula matches the assessed formula
- the packaging matches the reviewed artwork
- all required tests are final
- the CPSR is signed
- the PIF is accessible
- CPNP is complete
- Responsible Person information is correct
- claims match the evidence
- product variants are correctly linked
- distributor information is current
This final review prevents a technically completed project from becoming a non-compliant launch.
The most common causes of launch delays
Missing supplier information
Suppliers may provide marketing brochures but not the composition, impurity or toxicological data required for assessment.
Repeated formula changes
Each late modification can affect testing, ingredient labelling, exposure and safety conclusions.
Unclear variant strategy
Brands underestimate how different fragrances, colours or actives affect the assessment.
Late packaging decisions
The final container can affect stability, contamination risk, compatibility and label space.
Unsupported claims
The evidence does not match the strength or wording of the marketing statement.
Fragmented responsibility
No one manages dependencies between the brand, manufacturer, laboratory, assessor and Responsible Person.
Unrealistic launch dates
Commercial deadlines are announced before technical lead times have been assessed.
A practical planning sequence
The most efficient order is generally:
- Product concept and claim review
- Preliminary formula screening
- Supplier-document collection
- Formula freeze
- Testing and evidence programme
- Packaging compatibility
- Safety assessment
- PIF and label review
- CPNP notification
- Final release
- Post-market monitoring
Several activities can overlap, but their dependencies must be understood.
How Makrolife can support launch planning
Makrolife can create a coordinated testing and safety-assessment roadmap covering:
- document requirements
- formula review
- testing priorities
- supplier-data gaps
- safety assessment
- CPSR and PIF preparation
- label and claim consistency
- CPNP coordination
- result interpretation
- project milestones
- post-launch updates
The purpose is not simply to accelerate every task. It is to prevent avoidable repetition, reprinting and retesting.
Build the timeline before announcing the launch date
The fastest cosmetic project is rarely the one that skips steps. It is the one that identifies dependencies early and assigns clear responsibility.
Request a coordinated EU Cosmetic Launch Roadmap from Makrolife.
